drugset / Trial / NCT06672536
Multicenter, Phase I/II Study to Evaluate the Safety, Tolerability, PK and Efficacy of SCT520FF in Patients With nAMD
RandomizedParallel-groupTriple-blindTreatment
Summary
Multicenter, open-label, multi-dose study to evaluate the safety and tolerability in patients with nAMD treated with SCT520FF.
Timeline
- Start
- 2024-11-26
- Primary completion
- 2026-09-23
- Completion
- 2027-01-11
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Aflibercept | Protein / enzyme biologic | 2 mg | Intravitreal |
| Subject | SCT520FF | Unknown | 0.625 mg | Intravitreal |
| Subject | SCT520FF | Unknown | 1.25 mg | Intravitreal |
| Subject | SCT520FF | Unknown | 2.5 mg | Intravitreal |